At Merck KGaA, Darmstadt, Germany, our commitment to science and technology is at the heart of our mission. We drive innovations that not only address global challenges but also contribute to a sustainable future. Our dedication lies in developing solutions that create a positive impact on both people and the environment. We aspire to make groundbreaking discoveries that transform industries, enabling technological and scientific advancements to confront the pressing issues of today and tomorrow.
To empower researchers in their quest for scientific breakthroughs, we offer access to cutting-edge tools, services, and expertise essential for experimentation and product development. Our extensive portfolio is among the most comprehensive in the industry, focused on advancing science through sustainable solutions and scalable production materials that enhance research and development efforts.
Examples of Digital Solutions:
In the realm of digital solutions, we offer cutting-edge tools such as SYNTHIA® Retrosynthesis Software, which is expertly coded with over 140,000 chemistry rules. This software utilizes a database of more than 14 million commercial building blocks to generate complete synthetic pathways from known or commercial chemicals, regardless of the complexity involved. SYNTHIA® is literature-agnostic, providing unique strategies and disconnection ideas, particularly for compounds with limited or no literature precedents. Its predictions, grounded in chemistry rules rather than literature examples, complement existing literature-based programs.
Another key offering is AIDDISON™ AI in Drug Discovery, an advanced tool for ligand- and structure-based drug design. This innovative solution harnesses the power of artificial intelligence, machine learning, and computer-aided drug design to facilitate the creation of novel drugs, navigate extensive chemical spaces, predict ADMET properties, develop proprietary models, and deliver deeper insights through 3D visualizations. It also assesses compounds’ synthesizability and sources chemical libraries, streamlining the drug development process.
Examples of Chemical Biology Solutions:
Our commitment to Chemical Biology is reflected in our portfolio of innovative technologies and products designed to support researchers in drug discovery and development. Highlights include:
- ADC and Crosslinkers Selection Guide: A comprehensive resource to aid in the selection of antibody-drug conjugates and crosslinkers.
- Targeted Protein Degradation Building Blocks: We provide essential tools for targeted protein degradation, an emerging strategy in drug discovery. These reagents enable the development of small molecules that specifically target disease-causing proteins for degradation, opening new avenues for challenging drug targets.
- DNA Encoded Libraries (DYNA001 & DYNA002): Our DNA-encoded libraries are a powerful resource for screening and identifying potential drug candidates. By linking small molecules to unique DNA barcodes, researchers can simultaneously evaluate millions of compounds for their binding affinity to specific targets, significantly accelerating the drug discovery process.
- Reagents and Probes for Target Identification and Validation: To facilitate the identification and validation of drug targets, we offer a diverse range of high-quality reagents and probes. These tools provide researchers with critical insights into target biology and their viability for drug development.
- Micro Mapping Dexterity Kits: Our kits enable researchers to perform detailed mapping of protein interactions and epitopes. Understanding these precise interactions is vital for designing targeted and effective drug candidates, ultimately leading to therapies that specifically address disease-related proteins.
At Merck KGaA, Darmstadt, Germany, we are dedicated to advancing science and technology to create impactful solutions that drive innovation and foster a sustainable future.
About Drug Discovery Innovation Programme 2025
The Drug Discovery Innovation Programme, organized by World BI, is an exclusive, invitation-only event designed to connect leading scientists, researchers, and industry pioneers in a dynamic and collaborative environment.
Join us in person to gain insights from top experts in drug discovery and development, exploring the latest breakthroughs, emerging technologies, and innovative approaches shaping the future of the industry. With a forward-thinking agenda covering small molecule discovery, biologics, AI-driven translational medicine, and regulatory insights, DDIP 2025 will feature tailored sessions led by global leaders.
Bringing together visionaries from Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals, Amgen, Novo Nordisk, AbbVie, GSK, Exelixis, Insilico Medicine, and many more, this event is your opportunity to expand your knowledge, network with key stakeholders, and accelerate your drug development journey.